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In  recent  years  several  reports  have  appeared  in 
the literature  regarding  the  ability of various cell 
types  to  produce  acid  mucopolysaccharides 
(AMPS)  in  vitro.  At the same  time,  numerous ob- 
servations have been made on humans and on ex- 
perimental animals pointing out that the metabo- 
lism of AMPS  is influenced by various hormones. 
Interesting information could, therefore, be gained 
by  studying  the  production  of  AMPS  by  cells 
grmvn in vitro  and fed with media supplemented by 
hormones.  This  note  refers  to  observations made 
on  replicate  cultures  of human  embryonal  fibro- 
blasts  exposed  to  17-~-estradiol  and  to  human 
growth hormone. 
MATERIALS  AND  METHODS 
Subcutaneous  tissue  isolated  from  a  9-week-old 
human  embryo  was  minced  with  scissors  and  ex- 
planted on chicken plasma in T-30 flasks.  Cells grew 
out rapidly exhibiting the morphology of fibroblasts. 
Subculturing was  started  2  weeks  after primary  ex- 
plantation, and replicate cultures were prepared every 
10 days thereafter. Cell suspensions were prepared by 
trypsinization  (trypsin 0.05  per  cent,  Versene  0.002 
per cent in Moscona's saline solution).  In subcultur- 
ing,  1.25  X  106 cells suspended in 2.5 ml of medium 
were seeded in each of several T-30 flasks previously 
coated  with  an  extremely  thin  layer  of  chicken 
plasma.  The  feeding  solution  consisted  of:  Eagle's 
HeLa medium (supplemented with glutamine) 50 per 
cent;  whole  egg  ultrafiltrate  20  per  cent;  human 
placental serum  20 per  cent;  medium  from  the pre- 
vious feeding period  10  per cent.  Between transfers, 
the cultures were  washed and fed twice.  The control 
cultures were  fed with the above medimn,  while for 
the  experimental  cultures  the  following  hormones 
were added to the medium :  17-/3-estradiol, 0.1  #g/nil 
and  0.4  #g/ml;  human growth  hormone,  20  /.tg/ml 
and  100 #g/ml.  All experimental and control groups 
of cultures were carried on through 3 transfers.  Cells 
were  counted  with  a  hemocytometer.  The  quotient 
of the  number  of cells  at  the  beginning  and  at  the 
end  of each  culture  period  represented  the  growth 
increment  (GI).  The  medium  of all  the  flasks  from 
each group of cultures were pooled for AMPS deter- 
tion.  The  AMPS  were  extracted,  using  the  method 
described by Prince and Castor (1), and their amount 
estimated  as  uronic  acid  (UA-AMPS)  with  the 
carbazole  method  of  Dische  (2).  Gluc~onolactone 
was  used  as  standard.  Cell-bound  AMPS  were  not 
determined. The standard deviation calculated on 22 
samples of glucuronolactone solution (10 #g/ml)  was 
~0.891.  The amount of UA-AMPS  present in flesh 
medium  averaged 0.866  /.tg/ml  (dz0.179). 
OBSERVATIONS  AND  COMMENTS 
The  cells  exhibited  constant  morphological  and 
behavioral  features  throughout  this  study.  Seen 
with the light microscope  they appeared  as fibro- 
blast-like  cells  (Fig.  1).  Electron  micrographs 
prepared  by Dr.  George  D.  Pappas  of the Anat- 
omy Department,  College of Physicians and  Sur- 
geons,  Columbia  University,  indicated  that  these 
cells were  acceptable  as  fibroblasts.  Degenerative 
changes  were  occasionally  seen  especially  during 
the first  10 to 20 days after exposure to a  new hor- 
mone  or  to  a  different  hormonal  concentration. 
Experiments  in  which  the  cultures  exhibited 
degenerative changes were excluded. 
The  control  cultures  produced  AMPS  at  a 
283 reasonably  constant  rate  throughout  this  study. 
Although  the  capacity  for AMPS  production  by 
synovial cells may  be  decreased  or lost after pro- 
longed cultivation (3  6), fibroblasts from different 
sources  have  been  reported  to  produce  AMPS  in 
vitro  at  a  constant  rate  for  long  periods  of time 
(7-9).  "Fable I  illustrates the relationship between 
GI  and  amount  of UA-AMPS produced  by  four 
groups of control cultures.  It is apparent  that with 
these cells an increase in cell population is attended 
by an increase in UA-AMPS production. This is in 
agreement with the observation that in cultures of 
with  17-B-estradiol  with  the  GI  of  the  control 
cultures, it appears that the hormone has caused a 
depression  of the  growth  rate.  Several  reports  in 
the  past  have  indicated  that  estradiol  exerts  in 
vitro an  inhibitory effect on the growth of various 
cell  types  (12-16).  With  the  exception  of an  in- 
hibitory  effect  exerted  by  estradiol  on  the  in- 
corporation  of  S  '~5  in  cartilage  and  aorta  of  rats 
(17,  18),  by and large the estrogens seem to induce 
an  increase  in  AMPS  of the  ground  substance  of 
various organs (10,  19-25).  It is important to note 
that  in  quantitative  studies  of  AMPS  produced 
FmUI~E 1  Living culture of human embryonal fibroblasts ~0 hours after the l~th transfer.  Phase (on- 
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rat  fibroblasts  there  seems  to  be  a  direct  over-all 
relation  between  rate  of cell  population  increase 
and synthesis of AMPS (8, 9).  It has also been ob- 
served that  in the normal  human  breast  the peri- 
odical accumulation of AMPS in the intralobular 
and periductal stroma coincides with an increase in 
number of fibroblasts  (10). 
The effects of 17-/3-estradiol on the growth and 
on  the  AMPS  production  of these  cells are  sum- 
marized in Table II. According to Diczfaluzy and 
Magnusson  (11),  the  mean  value  for free  17-/3- 
estradiol in human cord blood is 3.6 #g/kg. There- 
fore, the addition of 0.1  7  of 17-/3-estradiol per ml 
of medium  represents approximately a  50-fold in- 
crease.  Comparing  the  GI of the  cultures  treated 
in  vitro one  is  mainly  concerned  with  the  non- 
sulfated  AMPS  since  it  has  been  observed  that 
cultures  of human  and  rat  fibroblasts  and  of hu- 
man  synovial cells produced  predominantly  non- 
sulfated  AMPS  (3,  8,  26,  27),  and  that  the small 
amount of chondroitin sulfate produced by some of 
these cells is not fully sulfated  (26).  In the present 
experiments  the  cultures  treated  with  0.1  gg/ml 
and  0.4/zg/ml  of  17-/3-estradiol  produced  signifi- 
cantly  greater  amounts  of  UA-AMPS  than  the 
control cultures in spite of a  much  slower growth 
rate.  It  has  been  reported  that  in  deteriorating 
cultures of synovial cells with decreasing cell popu- 
lations  the  apparent  rate  of hyaluronate  produc- 
tion  is  higher  than  that  of healthy  cultures  (5). 
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treated cultures did not show any deterioration of 
the  cells but only a  depression  of the  mitotic  ac- 
tivity. Furthermore, somewhat greater amounts of 
UA-AMPS were  produced  by those cultures with 
a  less depressed GI. 
The  effects  of the  human  growth  hormone  on 
TABLE  I 
UA-AMPS  Production  by  Control  Cultures* 
UA-AMPS  per unit 
GI  UA-AMPS  of G1 
Ng/ml  Ng/ml 
1.506  2.259  1.5 
1.636  2.408  1.41 
1.711  2.839  1.659 
1.908  4.077  2.136 
* Average  values  of  pooled  material  from  each 
group  of control  cultures. 
TABLE  II 
Effects  of  17-¢t-Estradiol  and  of  Growth  Hormone  on 
Rate of Growth and UA-AMPS Production* 
UA-AMPS per 
Hormone  GI  UA-AMPS unit of GI 
Ng/ml  Ng/ml  Ng/ml 
17-~-estradicl 
0.1  0.763  3.664  4.802 
0.1  1.049  4.544  4.331 
0.4  0.95  3.114  3.277 
0.4  1.00  4.043  4.043 
Growth  hormone 
20  1.071  2.971  2.774 
20  1.566  3.467  2.213 
100  1.564  2.322  1.484 
100  2.067  1.939  0.938 
* Average  values  of  pooled  material  from  each 
group  of experimental  cultures. 
these cells  (Table  II)  are difficult to evaluate  be- 
cause of the very small differences between the be- 
havior of the experimental cultures and that of the 
controls. The apparent lack of a stimulatory action 
on the G! is unexpected and is at variance with the 
increase in growth rate of human liver cells caused 
by growth hormone in vitro  (28).  The amounts of 
UA-AMPS produced by these fibroblasts when ex- 
posed to growth hormone are small and very close 
to those of the control cultures. The values for UA- 
AMPS produced per unit of GI indicated that the 
AMPS production was just above the upper limits 
of the normal when the growth hormone was used 
at the concentration of 20 #g/ml and .just below the 
lower limits of the normal when it was used at the 
concentration of  100  #g/ml,  This result is not en- 
tirely unexpected since growth hormone is known 
to produce an increase in uptake of S 3a in cartilage 
(29-34),  but  its  effects  seem  to  be  confined  to 
sulfated AMPS (33, 35). As mentioned earlier, the 
AMPS produced  by cell cultures are largely non- 
sulfated.  Nevertheless,  in  spite  of their smallness, 
the  differences  in  AMPS  production  by  the  cul- 
tures fed with these two concentrations of growth 
hormone  might  indicate  a  trend  to  be  revealed 
better by the use of smaller and larger doses of the 
hormone. 
SUMMARY  AND  CONCLUSIONS 
17-/3-estradiol  added  to  the  medium  (0.1  #g/ml 
and  0.4  #g/ml)  of  replicate  cultures  of  human 
embryonal  fibroblasts elicited  an increase  in  pro- 
duction of AMPS while depressing the growth rate 
of the  cells.  No  noticeable  effect  on  growth  rate 
of these cells nor on  their AMPS  production was 
exerted  by  human  growth  hormone  (20  #g/ml 
and 100 #g/ml). 
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